Lentivirus Purification
A more selective affinity approach to support functional recovery, impurity control and greater process consistency
HCP Log Reduction Value
In both resin and membrane formats at 0.5 min residence time
Dynamic Binding Capacity
Outperforming commercial affinity resin benchmarks across feed titers
Cycles
Resin Lifetime Demonstrated
0.5 M NaOH CIP with maintained HCP clearance and AAV recovery
VSV-G + Cocal
Cross-Pseudotype Capture
Single platform, no pseudotype-specific re-optimization required
LVV purification must preserve function, not simply recover particles.
Physical particle recovery alone does not establish that a purification step has preserved a useful product.
Envelope, particle structure and biological function are all affected by pH, conductivity, residence time, shear, surface interaction, concentration and hold conditions. A workflow that looks effective by physical titer can still lose infectious or transducing activity.
A purpose-designed affinity approach therefore pairs selective purification with conditions and material formats chosen around functional vector recovery.These impurities may affect multiple stages of the downstream workflow:
What the Lentiviral Purification Field Has Not Yet Answered
Several fundamental questions remain unresolved in lentiviral vector downstream processing. The answers to these problems determine the path towards a scalable, platform-compatible purification solution.
01
The in vivo shift raises the purification bar
As lentiviral programs move from ex vivo cell therapy toward in vivo delivery, expectations for purity, scalability and regulatory control rise sharply — and current workflows were not designed to meet that bar.
02
Particle fragility constrains the capture format
Enveloped LVV particles are sensitive to residence time and shear. Extended contact in a packed resin bed can compromise infectivity, making capture-format selection a core process-design constraint.
03
Pseudotype diversity fragments the workflow
The range of envelope pseudotypes introduces biophysical variability analogous to AAV serotypes, driving pseudotype-specific re-optimization and standing in the way of a single platform approach.
04
Legacy workflows do not scale cleanly
Ultracentrifugation, TFF and multi-step ion exchange were built for clinical-scale supply; adapting them to commercial volumes adds cost, complexity and yield pressure.
A purpose-designed approach to lentiviral purification
A useful LVV purification technology must improve selectivity and scalability while preserving the biological function that determines vector performance.
Preserve functional vector
Evaluate performance through infectious or transducing recovery, supported by appropriate particle, integrity and potency-related measurements.
Reduce pseudotype-specific redevelopment
Explore whether relevant envelope pseudotypes can begin from a more transferable framework, without assuming identical behaviour or eliminating process optimization.
Match the format to the particle
Select resin, membrane or alternative architectures according to mass transfer, residence time, throughput, pressure and vector-sensitivity requirements.
Support scale and process transfer
Build the approach around reproducibility, impurity clearance, cleaning strategy, analytical control and practical transfer into larger-scale manufacturing.
Preparing LVV Purification for the In Vivo Era
This application falls under our NAVIGATE program, connecting you with process expertise, new purification technologies, new insights and collabration opportunities to shape and implement a GMP-ready solution.
Professor Stefano Menegatti
NORTH CAROLINA STATE UNIVERSITY | CHROMAGENIX
Get in touch with us today.
Whether you’re exploring purification solutions, have a technical question, or want to learn more about our technologies, we’re here to help. Complete the form and a member of our team will be in touch shortly.